Invention Publication
- Patent Title: FUSION PROTEIN AND VACCINE
-
Application No.: US18032545Application Date: 2021-10-18
-
Publication No.: US20240091341A1Publication Date: 2024-03-21
- Inventor: Yasuo YOSHIOKA
- Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
- Applicant Address: JP Suita-shi, Osaka
- Assignee: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
- Current Assignee: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
- Current Assignee Address: JP Suita-shi, Osaka
- Priority: JP 20175599 2020.10.19
- International Application: PCT/JP2021/038496 2021.10.18
- Date entered country: 2023-04-18
- Main IPC: A61K39/215
- IPC: A61K39/215 ; A61P37/04 ; C07K14/005 ; C12N9/24
Abstract:
The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.
Information query
